TBIO

Translate Bio, Inc.

TBIO | News | $0.331 23K

(0.0% 1d) (-5.3% 1m) (-84.8% 1y) (0.0% 2d) (12.9% 3d) (13.6% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-19
Market Cap: $ 9,964,187
http://www.translate.bio
Sec Filling | Patents | 93 employees

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

fibrosis treatment

add to watch list Paper trade email alert is off

Press-releases

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Published: 2024-04-18 (Crawled : 13:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| 12.89% | O: 12.89% H: 0.0% C: 0.0%
mrna solutions dna bioxp platform

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| Email alert Add to watchlist
year financial results

Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Published: 2024-02-26 (Crawled : 14:30) - biospace.com/
TBIO | News | $0.331 23K

Health Technology

| -45.0% | O: -16.18% H: 16.09% C: 0.95%
financial results

Telesis Bio Reports Third Quarter 2023 Financial Results
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -14.22% | O: -0.02% H: 19.98% C: -0.24%
financial results

Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -44.64% | O: 0.01% H: 5.81% C: 4.52%
report financial results

Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -42.8% | O: 1.33% H: 6.58% C: 5.26%
dna commercial

Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
Published: 2023-09-28 (Crawled : 20:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -58.75% | O: 3.84% H: 0.0% C: -3.7%
bioxp commercial

Telesis Bio Appoints William J. Kullback Chief Financial Officer
Published: 2023-08-29 (Crawled : 20:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -63.95% | O: -0.84% H: 7.63% C: 6.78%
financial

Telesis Bio Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -69.14% | O: -2.88% H: 5.19% C: -2.96%
financial results

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
Published: 2023-08-03 (Crawled : 21:00) - globenewswire.com
TBIO | News | $0.331 23K

Health Technology

| -70.21% | O: -4.17% H: 3.99% C: -0.72%
report financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001209191-21-056067	4	2021-09-14	2021-09-14	Sell	S	300000	0
0001209191-21-056064	4	2021-09-14	2021-09-14	Sell	S	201800	0
0001209191-21-056062	4	2021-09-14	2021-09-14	Sell	S	325000	0
0001209191-21-056062	4	2021-09-14	2021-09-14	Sell	S	500000	0
0001209191-21-056062	4	2021-09-14	2021-09-14	Sell	S	503231	0